Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | MAOA | P21397 | 6/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23445095 | 0.75 | GLI1 (0.41) | KDM4EACHEMAOARARARARB | |
| SCHEMBL3681299 | 0.73 | FTO (0.61) | KDM4EFTOACHEMAOBMAOA | |
| SCHEMBL31292049 | 0.71 | FTO (0.53) | KDM4EFTOACHEMAOBMAOA | |
| SCHEMBL4951315 | 0.71 | FTO (0.53) | KDM4EFTOACHEMAOBMAOA | |
| Hydrochloric Acid SCHEMBL27956352 | 0.69 | FTO (0.52) | KDM4EFTOACHEMAOBMAOA | |
| SCHEMBL22938459 | 0.69 | RARB (0.46) | RARARARBRARG | |
| SCHEMBL29639995 | 0.69 | RARB (0.43) | RARARARBRARG | |
| SCHEMBL9432877 | 0.69 | FTO (0.55) | KDM4EFTOACHEMAOBMAOA | |
| SCHEMBL11036797 | 0.67 | PTPN1 (0.58) | KDM4EFTOACHEMAOBMAOA | |
| SCHEMBL29621714 | 0.67 | PTPN1 (0.58) | KDM4EFTOACHEMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2010032582-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | 国立大学法人鹿児島大学 (JP) | 2010-03-25 | — | — | WO | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | KDM4E 236/4885FTO 4401/4885ACHE 4588/4885 |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | KDM4E 2476/4885FTO 4736/4885ACHE 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.